These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10687751)

  • 21. Choto-san (kampo Medicine) for the treatment of headache.
    Dohi K; Aruga T; Satoh K; Shioda S
    Headache; 2004 Apr; 44(4):375. PubMed ID: 15109364
    [No Abstract]   [Full Text] [Related]  

  • 22. Diet and Japanese herbal medicine for recalcitrant atopic dermatitis: efficacy and safety.
    Kobayashi H; Mizuno N; Teramae H; Kutsuna H; Ueoku S; Onoyama J; Yamanaka K; Fujita N; Ishii M
    Drugs Exp Clin Res; 2004; 30(5-6):197-202. PubMed ID: 15700746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluvoxamine photosensitivity.
    Gillet-Terver MN; Modiano P; Tréchot P; Barbaud A; Schmutz JL
    Australas J Dermatol; 1996 Feb; 37(1):62. PubMed ID: 8936079
    [No Abstract]   [Full Text] [Related]  

  • 24. An interaction between carbamazepine and fluvoxamine.
    Martinelli V; Bocchetta A; Palmas AM; Del Zompo M
    Br J Clin Pharmacol; 1993 Dec; 36(6):615-6. PubMed ID: 12959283
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
    Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
    Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis.
    Eisen GM; Goldstein JL; Hanna DB; Rublee DA
    Aliment Pharmacol Ther; 2005 Mar; 21(5):591-8. PubMed ID: 15740543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicological considerations of Kampo medicines in clinical use.
    Ikegami F; Fujii Y; Satoh T
    Toxicology; 2004 May; 198(1-3):221-8. PubMed ID: 15138045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hair loss associated with fluvoxamine use.
    Parameshwar E
    Am J Psychiatry; 1996 Apr; 153(4):581-2. PubMed ID: 8599419
    [No Abstract]   [Full Text] [Related]  

  • 30. [Fluoxetine versus fluvoxamine for treatment of chronic pain].
    Ciaramella A; Grosso S; Poli P
    Minerva Anestesiol; 2000; 66(1-2):55-61. PubMed ID: 10736983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics of fluvoxamine-induced nausea.
    Ueda N; Yoshimura R; Shinkai K; Terao T; Nakamura J
    Psychiatry Res; 2001 Nov; 104(3):259-64. PubMed ID: 11728615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application.
    Tominaga K; Arakawa T
    J Gastroenterol; 2013 Apr; 48(4):452-62. PubMed ID: 23503839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Kampo therapy for inflammatory bowel diseases].
    Oikawa T; Ito G; Hanawa T
    Nihon Rinsho; 2012 Feb; 70 Suppl 1():365-9. PubMed ID: 23126119
    [No Abstract]   [Full Text] [Related]  

  • 35. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of fluvoxamine intoxication demonstrating nonlinear elimination pharmacokinetics.
    Spigset O; Ohman R
    J Clin Psychopharmacol; 1996 Jun; 16(3):254-5. PubMed ID: 8784660
    [No Abstract]   [Full Text] [Related]  

  • 37. [Chinese medicine for treatment of patients with prostatic hyperplasia].
    Fuse H; Akashi T
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():362-6. PubMed ID: 12599601
    [No Abstract]   [Full Text] [Related]  

  • 38. [Consensus on Chinese medical diagnosis and treatment of dyspepsia].
    ;
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 May; 30(5):533-7. PubMed ID: 20681287
    [No Abstract]   [Full Text] [Related]  

  • 39. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
    Spivak B; Strous RD; Shaked G; Shabash E; Kotler M; Weizman A
    J Clin Psychopharmacol; 2006 Apr; 26(2):152-6. PubMed ID: 16633143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical evaluation of Kampo medicine for the menopausal symptoms].
    Morimoto M
    Masui; 2007 Nov; 56 Suppl():S193-8. PubMed ID: 18051465
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.